 ADENOCARCINOMA OF LUNG, RESPONSE TO TYROS
|
ADENOCARCINOMA OF LUNG, SOMATIC
|
AMYOTROPHIC LATERAL SCLEROSIS 19
|
AORTIC ANEURYSM, FAMILIAL THORACIC 7
|
BRACHYDACTYLY, TYPE A2
|
BREAST CANCER, SUSCEPTIBILITY TO
|
CARDIOFACIOCUTANEOUS SYNDROME 1
|
CARDIOFACIOCUTANEOUS SYNDROME 3
|
CARDIOFACIOCUTANEOUS SYNDROME 4
|
CATARACT 6, AGE-RELATED CORTICAL
|
CEREBRAL INFARCTION, SUSCEPTIBILITY TO
|
CHRONIC MYELOID LEUKEMIA, RESISTANT TO IMATINIB
|
COFFIN-LOWRY SYNDROME
|
COLON CANCER, SOMATIC
|
COLORECTAL CANCER, SOMATIC
|
COLORECTAL CANCER, SOMATIC, INCLUDED;;
|
COWDEN DISEASE 6
|
CROUZON SYNDROME
|
DIABETES MELLITUS, INSULIN-RESISTANT, WITH ACANTHOSIS NIGRICANS
|
DIABETES MELLITUS, NONINSULIN-DEPENDENT
|
DIABETES MELLITUS, TYPE II
|
ENDOCRINE-CEREBROOSTEODYSPLASIA
|
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 2
|
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 2 (EIEE2)
|
FG SYNDROME 4
|
GLYCOGEN STORAGE DISEASE IXC
|
HARTSFIELD SYNDROME
|
HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 5
|
HYPOGONADOTROPIC HYPOGONADISM 2 WITH ANOSMIA
|
HYPOGONADOTROPIC HYPOGONADISM 2 WITH ANOSMIA, SUSCEPTIBILITY TO
|
HYPOGONADOTROPIC HYPOGONADISM 2 WITH OR WITHOUT ANOSMIA, SUSCEPTIBILITY
|
HYPOGONADOTROPIC HYPOGONADISM 2 WITHOUT ANOSMIA
|
HYPOGONADOTROPIC HYPOGONADISM 2 WITHOUT ANOSMIA, SUSCEPTIBILITY TO
|
IN
|
INSULIN RESISTANCE
|
INSULIN RESISTANCE, INCLUDED
|
IRAK4 DEFICIENCY
|
JUVENILE POLYPOSIS SYNDROME
|
LADD SYNDROME
|
LEUKEMIA, PHILADELPHIA CHROMOSOME-POSITIVE, RESISTANT TO IMATINIB
|
LYMPHOMA, NON-HODGKIN, SOMATIC
|
MALFORMATIONS
|
MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME
|
MELANOMA, MALIGNANT, SOMATIC
|
MENTAL RETARDATION AND MICROCEPHALY WITH PONTINE AND CEREBELLAR HYPOPLASIA
|
MENTAL RETARDATION, X-LINKED 30
|
MENTAL RETARDATION, X-LINKED, WITH NYSTAGMUS
|
NEPHRONOPHTHISIS 9 (NPHP9)
|
NEUROPATHY, HEREDITARY SENSORY, TYPE II
|
NONSMALL CELL LUNG CANCER, RESISTANCE TO TYROSINE KINASE INHIBITOR
|
NONSMALL CELL LUNG CANCER, RESPONSE TO TYROSINE KINASE INHIBITOR IN,
|
NOONAN SYNDROME 7
|
OBESITY, HYPERPHAGIA, AND DEVELOPMENTAL DELAY
|
OGUCHI DISEASE 2
|
PARKINSON DISEASE 8, AUTOSOMAL DOMINANT
|
PEUTZ-JEGHERS SYNDROME
|
PFEIFFER SYNDROME
|
PROSTATE CANCER, PROGRESSION AND METASTASIS OF
|
RETINITIS PIGMENTOSA 62
|
RETINITIS PIGMENTOSA 62 (RP62)
|
SCAPHOCEPHALY, MAXILLARY RETRUSION, AND MENTAL RETARDATION, INCLUDED
|
SHORT RIB-POLYDACTYLY SYNDROME 2A (SRPS2A)
|
SHORT RIB-POLYDACTYLY SYNDROME, TYPE IIA
|
SOMATIC
|
SPERMATOGENIC FAILURE 5
|
SPINOCEREBELLAR ATAXIA 14
|
T-CELL IMMUNODEFICIENCY, RECURRENT INFECTIONS, AUTOIMMUNITY, AND CARDIAC
|
TESTICULAR TUMOR, SOMATIC
|
THYROID CARCINOMA, FOLLICULAR, SOMATIC, INCLUDED
|
THYROID CARCINOMA, PAPILLARY, SOMATIC, INCLUDED;;|
|
TO
|
VARIANT OF UNKNOWN SIGNIFICANCE
|
VENOUS MALFORMATIONS, MULTIPLE CUTANEOUS AND MUCOSAL
|
Catalytic domain of Extracellular signal-Regulated Kinase 1 and 2-like Serine/Threonine Kinases. Serine/Threonine Kinases (STKs), Extracellular signal-regulated kinases 1 and 2 (ERK1/2) and Fus3 subfamily, catalytic (c) domain. STKs catalyze the transfer of the gamma-phosphoryl group from ATP to serine/threonine residues on protein substrates. This ERK1/2-like subfamily is part of a larger superfamily that includes the catalytic domains of other protein STKs, protein tyrosine kinases, RIO kinases, aminoglycoside phosphotransferase, choline kinase, and phosphoinositide 3-kinase. This subfamily is composed of the mitogen-activated protein kinases (MAPKs) ERK1, ERK2, baker's yeast Fus3, and similar proteins. MAPK pathways are important mediators of cellular responses to extracellular signals. ERK1/2 activation is preferentially by mitogenic factors, differentiation stimuli, and cytokines, through a kinase cascade involving the MAPK kinases MEK1/2 and a MAPK kinase kinase from the Raf family. ERK1/2 have numerous substrates, many of which are nuclear and participate in transcriptional regulation of many cellular processes. They regulate cell growth, cell proliferation, and cell cycle progression from G1 to S phase. Although the distinct roles of ERK1 and ERK2 have not been fully determined, it is known that ERK2 can maintain most functions in the absence of ERK1, and that the deletion of ERK2 is embryonically lethal. The MAPK, Fus3, regulates yeast mating processes including mating-specific gene expression, G1 arrest, mating projection, and cell fusion.
No pairwise interactions are available for this conserved domain.
